Table 1.
Main characteristics of included studies
| Authors | Year | Origin of population | N | Source of samples | Survival results | HR (95% CI) | Types of outcomes | Follow-up (month), n (range) | miRNAs assay |
|---|---|---|---|---|---|---|---|---|---|
| Zhang et al17 (group 1) | 2013 | People’s Republic of China | 138 | Tissue | DFS | 1.98 (0.95, 4.15) | CC (stage II) | 66 (50–86) | qRT-PCR |
| Zhang et al17 (group 2) | 2013 | People’s Republic of China | 137 | Tissue | DFS | 1.88 (0.95, 3.75) | CC (stage II) | 66 (50–86) | qRT-PCR |
| Zhang et al17 (group 3) | 2013 | People’s Republic of China | 460 | Tissue | DFS | 1.79 (1.22, 2.62) | CC (stage II) | 66 (50–86) | qRT-PCR |
| Kjaer-Frifeldt et al19 | 2012 | Denmark | 520 | Tissue | DFS | 1.41 (1.19, 1.67) | CC (stage II) | 84 | FISH |
| Nielsen et al16 (group 1) | 2011 | Denmark | 129 | Tissue | DFS | 2.39 (1.22, 4.69) | CC (stage II) | 60 | FISH |
| Nielsen et al16 (group 2) | 2011 | Denmark | 67 | Tissue | DFS | 0.96 (0.81, 1.15) | RC (stage II) | 60 | FISH |
| Shibuya et al13 | 2010 | Japan | 116 | Tissue | DFS | 2.53 (1.11, 5.38) | CRC | 44 (2–84) | qRT-PCR |
| Oue et al20 (Japan) | 2014 | Japan | 87 | Tissue | OS | 3.13 (1.20, 8.17) | CC (stage II, III) | 60 | qRT-PCR |
| Oue et al20 (Germany) | 2014 | Germany | 145 | Tissue | OS | 2.65 (1.06, 6.66) | CC (stage II) | 72 | qRT-PCR |
| Bovell et al10 | 2013 | USA | 55 | Tissue | OS | 3.25 (1.37, 7.72) | CRC (stage IV) | Black: 228 White: 180 |
qRT-PCR |
| Toiyama et al18 | 2013 | Japan | 153 | Tissue | OS | 0.59 (0.21, 1.63) | CRC | 60 | qRT-PCR |
| Chen et al21 | 2013 | Taiwan | 195 | Tissue | OS | 2.56 (1.43, 4.57) | CRC (stage I–IV) | 60 | qRT-PCR |
| Kjaer-Frifeldt et al19 | 2012 | Denmark | 520 | Tissue | OS | 1.08 (0.97, 1.22) | CC (stage II) | 84 | FISH |
| Nielsen et al16 (group 1) | 2011 | Denmark | 129 | Tissue | OS | 1.17 (1.02, 1.34) | CC (stage II) | 60 | FISH |
| Nielsen et al16 (group 2) | 2011 | Denmark | 67 | Tissue | OS | 0.97 (0.83, 1.13) | RC (stage II) | 60 | FISH |
| Shibuya et al13 | 2010 | Japan | 156 | Tissue | OS | 1.95 (1.05, 3.57) | CRC | 44 (2–84) | qRT-PCR |
| Schetter et al12 (Maryland, USA) | 2008 | Maryland, USA | 71 | Tissue | OS | 2.70 (1.30, 5.50) | CC (stage I–IV) | 68 | qRT-PCR |
| Schetter et al12 (Hong Kong) | 2008 | Hong Kong | 103 | Tissue | OS | 2.40 (1.40, 4.10) | CC (stage I–IV) | 84.6 | qRT-PCR |
| Toiyama et al18 | 2013 | Japan | 153 | Serum | OS | 4.12 (1.10, 15.40) | CRC | 60 | qRT-PCR |
| Menendez et al15 | 2013 | Spain | 102 | Serum | OS | 0.50 (0.25, 1.02) | CRC (stage I–IV) | 23 (0–36) | qRT-PCR |
| Liu et al14 | 2013 | People’s Republic of China | 166 | Serum | OS | 1.58 (0.77, 3.21) | CRC (stage I–IV) | 36.4 (4–53) | qRT-PCR |
Abbreviations: HR, hazard ratio; miRNAs, microRNAs; DFS, disease-free survival; CC, colon cancer; qRT-PCR, quantitative real-time polymerase chain reaction; FISH, fluorescence in situ hybridization; RC, rectal cancer; CRC, colorectal cancer; OS, overall survival.